Metabolomic profiling of cerebrospinal fluid to improve diagnosis and treatment monitoring of patients with inborn or acquired errors of metabolism

脑脊液代谢组学分析可改善先天性或后天性代谢错误患者的诊断和治疗监测

• 批准号: MR/V03801X/1
• 负责人: Simon Pope
• 金额: $ 28.96万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FV03801X%2F1
• 关键词: Metabolomic; profiling; cerebrospinal; fluid; improve

Summary The objective of this project is to develop new tests, using modern technology, to improve our diagnostic service. Our diagnostic laboratory is an NHS national referral centre for patients suspected of having abnormalities in brain metabolism, particularly with regards to neurotransmitter and vitamin metabolism (see below). The sample type that we use for diagnosis is cerebrospinal fluid (CSF). We receive around 1000 CSF samples per year. Many of these samples are from young children with suspected genetic disorders affecting brain metabolism, causing them to have clinical symptoms such as movement disorders, developmental delay or epileptic seizures. We also receive CSF samples from older patients for treatment monitoring or to identify potentially treatable symptoms in patients with neuroinflammation, movement disorders (such as Parkinson's disease) or neurodegeneration.Cerebrospinal fluid (often abbreviated as CSF) is the fluid that surrounds the brain and spinal cord. Nutrients from the blood are transported into the CSF via the blood-brain barrier. The CSF then takes these nutrients to brain cells and removes waste products from the brain to be transported back across the blood-brain barrier and either be recycled or excreted from the body. In contrast to blood, CSF is clear in colour and has little or no cells. This makes it a nice clean matrix for looking at brain metabolism. The small molecules that we measure in body fluids, such as blood and CSF, are known as metabolites and help us to understand how the organs of the body are using and recycling nutrients from the diet. Studying the metabolites can also help us to identify and diagnose disorders where the body is not using or recycling these nutrients effectively.Our current CSF service results in a definitive diagnosis in only around 5% of patients. However, almost 50% have abnormalities of unknown significance in our current tests and this is likely to be higher if more brain metabolites could be measured. These patients are likely to have an undiagnosed neurometabolic condition. The aim of this project is to use modern techniques to increase the number of metabolites that we can measure so that we can diagnose this group of currently undiagnosed patients. We currently have four tests that measure metabolites in CSF. These tests are based on 30 year old technology but are very reliable and we have many years of experience of interpreting the results from these tests. These tests measure neurotransmitter metabolites and vitamins/co-factors that are required for neurotransmitter synthesis and many other essential chemicals in the brain. With these four tests we currently measure 10 metabolites, in total, in CSF.The new tests that we will develop will use mass spectrometry, a modern ultra-sensitive and rapid technique. This technology will allow us to increase the number of metabolites that we can measure from 10 currently to over 30. Although mass spectrometers are capable of measuring many more metabolites, we initially intend to focus on a smaller number (around 30) and expand as required. This is so that we can focus on specific pathways that are hypothesised to be affected in our group of patients. This will also make it easier to ensure that the method is robust, reproducible and accurate.At the moment, our diagnostic assays are very good at highlighting defects in brain neurotransmitter or vitamin metabolism. However, due to the limited number of metabolites that we measure, we can not always define the exact cause and functional effect of the defect. A modern mass spectrometry method will give us much greater insight into brain metabolism and allow us to characterise and diagnose currently undiagnosed disorders. It will also allow us to suggest and monitor treatments better. This will in turn improve the lives of children and families affected by these devastating but often treatable diseases affecting brain metabolism.

该项目的目标是利用现代技术开发新的检测方法，以改善我们的诊断服务。我们的诊断实验室是NHS的全国转诊中心，为疑似大脑代谢异常的患者提供咨询，特别是在神经递质和维生素代谢方面(见下文)。我们用于诊断的样本类型是脑脊液(CSF)。我们每年收到大约1000份脑脊液样本。这些样本中有许多来自疑似患有影响大脑新陈代谢的遗传疾病的幼儿，导致他们出现运动障碍、发育迟缓或癫痫发作等临床症状。我们还从老年患者那里接收脑脊液样本，用于治疗监测或确定患有神经炎、运动障碍(如帕金森氏病)或神经退行性变的患者的潜在可治疗症状。脑脊液(通常缩写为CSF)是包围大脑和脊髓的液体。血液中的营养物质通过血脑屏障输送到脑脊液中。然后，脑脊液将这些营养物质带到脑细胞，从大脑中清除废物，通过血脑屏障运回，然后回收利用或从体内排泄出来。与血液不同的是，脑脊液颜色清晰，几乎没有细胞。这使得它成为观察大脑新陈代谢的一个很好的干净矩阵。我们在体液中测量的小分子，如血液和脑脊液，被称为代谢物，帮助我们了解身体器官如何利用和循环饮食中的营养。研究这些代谢物还可以帮助我们识别和诊断身体没有有效利用或循环这些营养物质的疾病。我们目前的脑脊液服务只在大约5%的患者中得到了明确的诊断。然而，在我们目前的测试中，几乎50%的人有未知意义的异常，如果能测量到更多的大脑代谢物，这个比例可能会更高。这些患者很可能患有未确诊的神经代谢疾病。这个项目的目的是使用现代技术来增加我们可以测量的代谢物的数量，以便我们能够诊断这组目前未被诊断的患者。我们目前有四种测试来测量脑脊液中的代谢物。这些测试基于有30年历史的技术，但非常可靠，我们有多年解释这些测试结果的经验。这些测试测量神经递质代谢物和维生素/辅助因子，这是神经递质合成和大脑中许多其他基本化学物质所必需的。通过这四种测试，我们目前总共测量了CSF中的10种代谢物。我们将开发的新测试将使用质谱学，这是一种现代的超灵敏和快速技术。这项技术将使我们能够测量的代谢物数量从目前的10种增加到30多种。虽然质谱仪能够测量更多的代谢物，但我们最初打算专注于较少的数量(约30个)，并根据需要进行扩展。这是为了我们可以专注于假设在我们的患者组中受到影响的特定路径。这也将使我们更容易确保该方法是健壮的、可重复性的和准确的。目前，我们的诊断分析非常擅长于突出大脑神经递质或维生素代谢的缺陷。然而，由于我们测量的代谢物数量有限，我们不能总是确定缺陷的确切原因和功能影响。现代质谱学方法将使我们更深入地了解大脑新陈代谢，并使我们能够描述和诊断目前未诊断的疾病。它还将使我们能够更好地建议和监测治疗。这反过来将改善受这些影响大脑新陈代谢的破坏性疾病影响的儿童和家庭的生活。

项目成果

Laboratory guide to the methods in biochemical genetics

• DOI: 10.1007/978-3-540-76698-8
• 发表时间: 2008-05
• 作者: N. Blau;M. Duran;K. Gibson

Advances in methods to analyse cardiolipin and their clinical applications.

• DOI: 10.1016/j.trac.2022.116808
• 发表时间: 2022-12
• 期刊: Trends in analytical chemistry : TRAC
• 作者: Bautista JS;Falabella M;Flannery PJ;Hanna MG;Heales SJR;Pope SAS;Pitceathly RDS
• 通讯作者: Pitceathly RDS

Gene therapy for Dopamine transporter deficiency syndrome: Infantile Parkinsonism-dystonia

多巴胺转运蛋白缺乏综合征的基因治疗：婴儿帕金森症-肌张力障碍

• 发表时间: 2021
• 期刊: HUMAN GENE THERAPY
• 影响因子: 4.2
• 作者: Ng J.

Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.

• DOI: 10.1126/scitranslmed.aaw1564
• 发表时间: 2021-05-19
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Ng J;Barral S;De La Fuente Barrigon C;Lignani G;Erdem FA;Wallings R;Privolizzi R;Rossignoli G;Alrashidi H;Heasman S;Meyer E;Ngoh A;Pope S;Karda R;Perocheau D;Baruteau J;Suff N;Antinao Diaz J;Schorge S;Vowles J;Marshall LR;Cowley SA;Sucic S;Freissmuth M;Counsell JR;Wade-Martins R;Heales SJR;Rahim AA;Bencze M;Waddington SN;Kurian MA
• 通讯作者: Kurian MA

Aromatic l-amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies.

• DOI: 10.1093/brain/awab123
• 发表时间: 2021-09-04
• 期刊: Brain : a journal of neurology
• 作者: Rossignoli G;Krämer K;Lugarà E;Alrashidi H;Pope S;De La Fuente Barrigon C;Barwick K;Bisello G;Ng J;Counsell J;Lignani G;Heales SJR;Bertoldi M;Barral S;Kurian MA
• 通讯作者: Kurian MA